JOHNSON & JOHNSON

NYSE: JNJ (Johnson & Johnson)

Last update: 15 hours ago

152.38

-2.84 (-1.83%)

  • 1D -1.83%
  • 5D -2.60%
  • 1M -0.07%
  • 6M 5.27%
  • YTD 5.80%
  • 1Y 4.62%
  • 5Y 6.25%
Previous Close 155.22
Open 154.97
Volume 4,067,762
Avg. Volume (3M) 9,014,922
Market Cap 366,636,957,696
Price / Earnings (TTM) 16.95
Price / Earnings (Forward) 14.86
Price / Sales 4.27
Price / Book 4.84
52 Weeks Range
140.68 (-7%) — 169.99 (11%)
Earnings Date 16 Jul 2025
TTM Dividend Yield 2.44%
Profit Margin 24.42%
Operating Margin (TTM) 29.41%
Diluted EPS (TTM) 8.99
Quarterly Revenue Growth (YOY) 2.40%
Quarterly Earnings Growth (YOY) 237.90%
Total Debt/Equity (MRQ) 66.90%
Current Ratio (MRQ) 1.26
Operating Cash Flow (TTM) 24.78 B
Levered Free Cash Flow (TTM) 16.80 B
Return on Assets (TTM) 7.77%
Return on Equity (TTM) 29.45%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Mixed
Drug Manufacturers - General (Global) Bearish Mixed
Stock Johnson & Johnson Bearish Bearish

AIStockmoo Score

0.4
Analyst Consensus 1.0
Insider Activity NA
Price Volatility 1.0
Technical Moving Averages -2.5
Technical Oscillators 2.0
Average 0.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
JNJ 367 B 2.44% 16.95 4.84
ABBV 337 B 3.34% 81.22 239.36
PFE 136 B 5.29% 17.39 1.54
BMY 102 B 3.62% 18.44 5.73
GSK 84 B 2.77% 20.16 4.48
LLY 691 B 0.53% 62.09 45.06

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.06%
% Held by Institutions 74.02%
52 Weeks Range
140.68 (-7%) — 169.99 (11%)
Price Target Range
153.00 (0%) — 181.00 (18%)
High 181.00 (RBC Capital, 18.78%) Buy
Median 165.00 (8.28%)
Low 153.00 (Leerink Partners, 0.41%) Hold
Average 166.14 (9.03%)
Total 3 Buy, 4 Hold
Avg. Price @ Call 152.44
Firm Date Target Price Call Price @ Call
RBC Capital 05 Jun 2025 181.00 (18.78%) Buy 153.66
16 Apr 2025 181.00 (18.78%) Buy 153.91
Leerink Partners 13 May 2025 153.00 (0.41%) Hold 148.44
Barclays 17 Apr 2025 165.00 (8.28%) Hold 157.47
Morgan Stanley 16 Apr 2025 169.00 (10.91%) Hold 153.91
09 Apr 2025 164.00 (7.63%) Hold 150.97
Raymond James 16 Apr 2025 164.00 (7.63%) Buy 153.91
14 Apr 2025 162.00 (6.31%) Buy 154.36
B of A Securities 10 Apr 2025 159.00 (4.34%) Hold 148.69
Goldman Sachs 09 Apr 2025 172.00 (12.88%) Buy 150.97

No data within this time range.

  • 3M
Date Type Details
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
17 Jun 2025 CNBC Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
15 Jun 2025 Announcement Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
13 Jun 2025 Announcement Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
12 Jun 2025 Announcement New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
11 Jun 2025 Announcement New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
10 Jun 2025 Announcement Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
03 Jun 2025 Announcement Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
03 Jun 2025 Announcement DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
03 Jun 2025 Announcement Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
03 Jun 2025 Announcement Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
28 May 2025 Announcement Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
23 May 2025 Announcement FDA Panel Reiterates the Cancer Risks of Talc
21 May 2025 Announcement Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
20 May 2025 Announcement Dean Omar Branham Shirley Recognized Twice Among ALM’s 2024 Top 100 Verdicts
20 May 2025 Announcement U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
18 May 2025 Announcement Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson’s Biosense Webster Medical Technology Unit
15 May 2025 Announcement Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
14 May 2025 Announcement Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
12 May 2025 CNBC Trump signs order aiming to cut some U.S. drug prices to match lower ones abroad
09 May 2025 Announcement Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
08 May 2025 Announcement Johnson & Johnson expands efforts to champion the nursing workforce globally
05 May 2025 Announcement TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
05 May 2025 Announcement TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
05 May 2025 CNBC Trump signs order to boost domestic drug manufacturing as pharma tariffs loom
30 Apr 2025 Announcement Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
28 Apr 2025 Announcement Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
26 Apr 2025 Announcement Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
26 Apr 2025 Announcement Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
24 Apr 2025 CNBC Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
21 Apr 2025 Announcement Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
16 Apr 2025 CNBC Medical product manufacturers are divided over Trump's tariffs
16 Apr 2025 Announcement Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
15 Apr 2025 Announcement Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
15 Apr 2025 Announcement Johnson & Johnson Reports Q1 2025 Results
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
10 Apr 2025 Announcement Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
08 Apr 2025 Announcement Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
07 Apr 2025 Announcement Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
04 Apr 2025 Announcement TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
02 Apr 2025 Announcement Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
01 Apr 2025 Announcement Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
01 Apr 2025 Announcement Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts
26 Mar 2025 Announcement RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
26 Mar 2025 Announcement New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
21 Mar 2025 Announcement Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
20 Mar 2025 Announcement RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
20 Mar 2025 Announcement U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
18 Mar 2025 Announcement Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
Show more
TTM Dividend Yield 2.44%
5Y Average Dividend Yield 2.78%
Payout Ratio 55.17%
Expected Next Dividend Payment Sep 2025
Ex Date Announcement Date Payment Date Details
18 Feb 2025 02 Jan 2025 04 Mar 2025 1.24 Cash
26 Nov 2024 15 Oct 2024 10 Dec 2024 1.24 Cash
27 Aug 2024 17 Jul 2024 10 Sep 2024 1.24 Cash
20 May 2024 16 Apr 2024 04 Jun 2024 1.24 Cash
16 Feb 2024 02 Jan 2024 05 Mar 2024 1.19 Cash
20 Nov 2023 19 Oct 2023 05 Dec 2023 1.19 Cash
25 Aug 2023 20 Jul 2023 07 Sep 2023 1.19 Cash
22 May 2023 18 Apr 2023 06 Jun 2023 1.19 Cash
17 Feb 2023 03 Jan 2023 07 Mar 2023 1.13 Cash
21 Nov 2022 19 Oct 2022 06 Dec 2022 1.13 Cash
22 Aug 2022 18 Jul 2022 06 Sep 2022 1.13 Cash
23 May 2022 19 Apr 2022 07 Jun 2022 1.13 Cash
18 Feb 2022 04 Jan 2022 08 Mar 2022 1.06 Cash
22 Nov 2021 21 Oct 2021 07 Dec 2021 1.06 Cash
23 Aug 2021 19 Jul 2021 07 Sep 2021 1.06 Cash
24 May 2021 06 May 2021 08 Jun 2021 1.06 Cash
22 Feb 2021 04 Jan 2021 09 Mar 2021 1.01 Cash
23 Nov 2020 22 Oct 2020 08 Dec 2020 1.01 Cash
24 Aug 2020 20 Jul 2020 08 Sep 2020 1.01 Cash
22 May 2020 14 Apr 2020 09 Jun 2020 1.01 Cash
24 Feb 2020 02 Jan 2020 10 Mar 2020 0.95 Cash
25 Nov 2019 18 Oct 2019 10 Dec 2019 0.95 Cash
26 Aug 2019 16 Jul 2019 10 Sep 2019 0.95 Cash
24 May 2019 26 Apr 2019 11 Jun 2019 0.95 Cash
25 Feb 2019 02 Jan 2019 12 Mar 2019 0.9 Cash
26 Nov 2018 18 Oct 2018 11 Dec 2018 0.9 Cash
27 Aug 2018 17 Jul 2018 11 Sep 2018 0.9 Cash
25 May 2018 26 Apr 2018 12 Jun 2018 0.9 Cash
26 Feb 2018 02 Jan 2018 13 Mar 2018 0.84 Cash
27 Nov 2017 19 Oct 2017 12 Dec 2017 0.84 Cash
25 Aug 2017 17 Jul 2017 12 Sep 2017 0.84 Cash
25 May 2017 27 Apr 2017 13 Jun 2017 0.84 Cash
24 Feb 2017 03 Jan 2017 14 Mar 2017 0.8 Cash
18 Nov 2016 20 Oct 2016 06 Dec 2016 0.8 Cash
19 Aug 2016 18 Jul 2016 06 Sep 2016 0.8 Cash
20 May 2016 28 Apr 2016 07 Jun 2016 0.8 Cash
19 Feb 2016 04 Jan 2016 08 Mar 2016 0.75 Cash
20 Nov 2015 22 Oct 2015 08 Dec 2015 0.75 Cash
21 Aug 2015 20 Jul 2015 08 Sep 2015 0.75 Cash
21 May 2015 23 Apr 2015 09 Jun 2015 0.75 Cash
20 Feb 2015 05 Jan 2015 10 Mar 2015 0.7 Cash
21 Nov 2014 16 Oct 2014 09 Dec 2014 0.7 Cash
22 Aug 2014 21 Jul 2014 09 Sep 2014 0.7 Cash
22 May 2014 24 Apr 2014 10 Jun 2014 0.7 Cash
21 Feb 2014 02 Jan 2014 11 Mar 2014 0.66 Cash
22 Nov 2013 17 Oct 2013 10 Dec 2013 0.66 Cash
23 Aug 2013 15 Jul 2013 10 Sep 2013 0.66 Cash
23 May 2013 25 Apr 2013 11 Jun 2013 0.66 Cash
22 Feb 2013 02 Jan 2013 12 Mar 2013 0.61 Cash
23 Nov 2012 17 Oct 2012 11 Dec 2012 0.61 Cash
24 Aug 2012 16 Jul 2012 11 Sep 2012 0.61 Cash
24 May 2012 26 Apr 2012 12 Jun 2012 0.61 Cash
24 Feb 2012 03 Jan 2012 13 Mar 2012 0.57 Cash
25 Nov 2011 21 Oct 2011 13 Dec 2011 0.57 Cash
26 Aug 2011 18 Jul 2011 13 Sep 2011 0.57 Cash
26 May 2011 28 Apr 2011 14 Jun 2011 0.57 Cash
25 Feb 2011 03 Jan 2011 15 Mar 2011 0.54 Cash
26 Nov 2010 21 Oct 2010 14 Dec 2010 0.54 Cash
27 Aug 2010 19 Jul 2010 14 Sep 2010 0.54 Cash
27 May 2010 22 Apr 2010 15 Jun 2010 0.54 Cash
19 Feb 2010 04 Jan 2010 09 Mar 2010 0.49 Cash
20 Nov 2009 22 Oct 2009 08 Dec 2009 0.49 Cash
21 Aug 2009 20 Jul 2009 08 Sep 2009 0.49 Cash
21 May 2009 23 Apr 2009 09 Jun 2009 0.49 Cash
20 Feb 2009 05 Jan 2009 10 Mar 2009 0.46 Cash
21 Nov 2008 16 Oct 2008 09 Dec 2008 0.46 Cash
22 Aug 2008 21 Jul 2008 09 Sep 2008 0.46 Cash
22 May 2008 24 Apr 2008 10 Jun 2008 0.46 Cash
22 Feb 2008 02 Jan 2008 11 Mar 2008 0.415 Cash
23 Nov 2007 18 Oct 2007 11 Dec 2007 0.415 Cash
24 Aug 2007 16 Jul 2007 11 Sep 2007 0.415 Cash
24 May 2007 26 Apr 2007 12 Jun 2007 0.415 Cash
23 Feb 2007 03 Jan 2007 13 Mar 2007 0.375 Cash
24 Nov 2006 19 Oct 2006 12 Dec 2006 0.375 Cash
25 Aug 2006 18 Jul 2006 12 Sep 2006 0.375 Cash
25 May 2006 27 Apr 2006 13 Jun 2006 0.375 Cash
18 Nov 2005 20 Oct 2005 13 Dec 2005 0.33 Cash
19 Aug 2005 18 Jul 2005 13 Sep 2005 0.33 Cash
13 May 2005 28 Apr 2005 07 Jun 2005 0.33 Cash
11 Feb 2005 04 Jan 2005 08 Mar 2005 0.285 Cash
12 Nov 2004 22 Oct 2004 07 Dec 2004 0.285 Cash
13 Aug 2004 20 Jul 2004 07 Sep 2004 0.285 Cash
14 May 2004 22 Apr 2004 08 Jun 2004 0.285 Cash
12 Feb 2004 05 Jan 2004 09 Mar 2004 0.24 Cash
14 Nov 2003 16 Oct 2003 09 Dec 2003 0.24 Cash
15 Aug 2003 22 Jul 2003 09 Sep 2003 0.24 Cash
16 May 2003 24 Apr 2003 10 Jun 2003 0.24 Cash
13 Feb 2003 06 Jan 2003 11 Mar 2003 0.205 Cash
15 Nov 2002 15 Oct 2002 10 Dec 2002 0.205 Cash
16 Aug 2002 15 Jul 2002 10 Sep 2002 0.205 Cash
17 May 2002 25 Apr 2002 11 Jun 2002 0.205 Cash
14 Feb 2002 02 Jan 2002 12 Mar 2002 0.18 Cash
16 Nov 2001 18 Oct 2001 11 Dec 2001 0.18 Cash
17 Aug 2001 16 Jul 2001 11 Sep 2001 0.18 Cash
18 May 2001 26 Apr 2001 12 Jun 2001 0.36 Cash
15 Feb 2001 02 Jan 2001 13 Mar 2001 0.32 Cash
17 Nov 2000 16 Oct 2000 12 Dec 2000 0.32 Cash
18 Aug 2000 17 Jul 2000 12 Sep 2000 0.32 Cash
19 May 2000 19 Apr 2000 13 Jun 2000 0.32 Cash
11 Feb 2000 03 Jan 2000 07 Mar 2000 0.28 Cash
12 Nov 1999 18 Oct 1999 07 Dec 1999 0.28 Cash
13 Aug 1999 19 Jul 1999 07 Sep 1999 0.28 Cash
14 May 1999 22 Apr 1999 08 Jun 1999 0.28 Cash
11 Feb 1999 04 Jan 1999 09 Mar 1999 0.25 Cash
13 Nov 1998 19 Oct 1998 08 Dec 1998 0.25 Cash
14 Aug 1998 20 Jul 1998 08 Sep 1998 0.25 Cash
15 May 1998 23 Apr 1998 09 Jun 1998 0.25 Cash
12 Feb 1998 02 Jan 1998 10 Mar 1998 0.22 Cash
14 Nov 1997 20 Oct 1997 09 Dec 1997 0.22 Cash
15 Aug 1997 21 Jul 1997 09 Sep 1997 0.22 Cash
16 May 1997 24 Apr 1997 10 Jun 1997 0.22 Cash
13 Feb 1997 02 Jan 1997 11 Mar 1997 0.19 Cash
15 Nov 1996 21 Oct 1996 10 Dec 1996 0.19 Cash
16 Aug 1996 15 Jul 1996 10 Sep 1996 0.19 Cash
17 May 1996 25 Apr 1996 11 Jun 1996 0.38 Cash
15 Feb 1996 02 Jan 1996 12 Mar 1996 0.33 Cash
10 Nov 1995 16 Oct 1995 05 Dec 1995 0.33 Cash
11 Aug 1995 17 Jul 1995 05 Sep 1995 0.33 Cash
10 May 1995 27 Apr 1995 06 Jun 1995 0.33 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.24 1 0.81
2024 4.91 4 3.40
2023 4.70 4 3.00
2022 4.45 4 2.52
2021 4.19 4 2.45
2020 3.98 4 2.53
2019 3.75 4 2.57
2018 3.54 4 2.74
2017 3.32 4 2.38
2016 3.15 4 2.73
2015 2.95 4 2.87
2014 2.76 4 2.64
2013 2.59 4 2.83
2012 2.40 4 3.42
2011 2.25 4 3.43
2010 2.11 4 3.41
2009 1.93 4 3.00
2008 1.80 4 3.00
2007 1.62 4 2.43
2006 1.13 3 1.70
2005 1.28 4 2.12
2004 1.10 4 1.73
2003 0.925 4 1.79
2002 0.795 4 1.48
2001 1.04 4 1.76
2000 1.24 4 2.36
1999 1.09 4 2.34
1998 0.970 4 2.31
1997 0.850 4 2.58
1996 1.09 4 4.38
1995 0.990 3 4.63
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria